StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Stock analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Wednesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Up 1.8 %

EGRX stock opened at $0.56 on Wednesday. The stock has a 50-day moving average price of $0.69 and a two-hundred day moving average price of $2.76. Eagle Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $6.81.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Large investors have recently bought and sold shares of the company. Creative Planning bought a new position in Eagle Pharmaceuticals in the third quarter valued at $59,000. Mackenzie Financial Corp acquired a new position in shares of Eagle Pharmaceuticals during the 2nd quarter worth about $60,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at about $65,000. Fidelis Capital Partners LLC acquired a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $71,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Eagle Pharmaceuticals during the second quarter worth about $76,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.